Stem Cell Therapy For Autism: ICMR-Funded Indian Trial Raises Hope

The Supreme Court's intervention against the unregulated use of stem cell therapy for autism has paved the way for a government-funded clinical trial, marking an important shift from commercial claims of a cure to scientifically monitored research.

The multicentre randomised controlled trial has been proposed at two tertiary-care centres — AIIMS, New Delhi, and Amrita Hospital, Kochi — with Indian Council of Medical Research (ICMR) funding.

The move comes amid concerns that vulnerable families, desperate for treatment options for children with autism spectrum disorder (ASD), have been exposed to expensive and unproven interventions.

The proposed ICMR-funded randomised controlled trial (RCT) follows the Supreme Court's January 30, 2026 judgement in Yash Charitable Trust & Others versus Union of India, which held that stem cell therapy for autism cannot be offered as a routine clinical service outside an approved and monitored research or clinical-trial setting.

The court observed that the therapeutic use of stem cells for autism was not recognised as sound and relevant medical practice in view of the scientific evidence and regulatory standards available at present.

The petition had highlighted how parents and carers, often unaware of the scientific and regulatory limitations, were spending substantial sums in the hope of improving their children's condition.

Following the Supreme Court ruling, the ICMR wrote to the National Medical Commission (NMC) on March 10, 2026, seeking wider dissemination of the regulatory requirements governing stem cell therapy.

The NMC, through an advisory dated March 25, asked all medical colleges and institutions to ensure compliance with the Supreme Court's directions.

The proposed trial is intended to provide a regulated avenue for investigating the intervention and addressing concerns surrounding patients who had been receiving such procedures. Its scientific design, eligibility criteria, informed consent process, safety monitoring and long-term follow-up will be crucial.

The National Stem Cell Research Regulation Committee (NSRC) issued a public notice on November 5, inviting suggestions from healthcare professionals, parents, carers, patient organisations and other stakeholders, particularly on participant eligibility. NSRC was constituted in March 2026 by the Department of Health Research to oversee and regulate research involving stem cells subjected to minimal or less-than-minimal manipulation.

International research has already generated preliminary interest in the potential of stem cells to influence neuroinflammation, immune responses and neuronal functioning associated with autism.

A randomised, double-blind, placebo-controlled study published in Stem Cell Research & Therapy in June 2026 reported improvements in some social responsiveness measures among children receiving umbilical cord blood-derived cell therapy. However, the study involved only 34 children and had a short follow-up period, limiting conclusions about long-term effectiveness and safety.

Similarly, a review published in the Journal of Translational Medicine in March 2026 also examined emerging clinical evidence on mesenchymal stem cell-based interventions. It highlighted the need for larger, well-designed trials and standardised treatment protocols before these procedures can be considered for clinical use.

However, these findings offer research leads, not proof of an established treatment. Different stem cell preparations and administration methods also make it important not to generalise results from one study to another.

The urgency of exploring new treatment options must also be seen against the larger burden of autism in India. The country does not yet have a comprehensive, nationally representative estimate of the number of people living with the condition. A clinical practice guideline published in the Indian Journal of Psychiatry in January 2025 cited prevalence estimates ranging from 0.74% to 1.68% among Indian children aged two to nine years.

Autism is a lifelong neurodevelopmental condition affecting social communication and interaction, with restricted or repetitive patterns of behaviour, interests or activities. The support required varies considerably, with some individuals needing substantial assistance in everyday activities and others able to study, work and live independently with appropriate support.

Early identification and intervention can improve communication, social interaction, learning and daily living skills. However, access to developmental paediatricians, child psychiatrists, speech and language therapists, occupational therapists and special educators remains uneven, particularly outside major cities.

There is currently no established cure for autism. Management relies on individualised developmental and behavioural interventions, speech and language therapy, occupational therapy, educational support and parent-mediated programmes.

Medicines may be prescribed for associated conditions such as severe irritability, hyperactivity, anxiety and sleep difficulties, but they do not treat the core features of autism.